Hansa Biopharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Net Income	-656.57	-534.11	-807.24
Depreciation & Amortization	-	38.76	28.06
Other Adjustments	133.47	-16.21	168.33
Change in Receivables	-	-35.16	-66.94
Changes in Accounts Payable	-	16.44	-49.35
Changes in Other Operating Activities	-61.63	-56.5	-11.77
Operating Cash Flow	-579.63	-549.17	-674.88
Capital Expenditures	-	-	-0.12
Investing Cash Flow	15	-	-0.12
Long-Term Debt Issued	271.11	-	-
Long-Term Debt Repaid	-136.87	-	-
Net Long-Term Debt Issued (Repaid)	134.24	-	-
Issuance of Common Stock	647.53	865.6	354.31
Net Common Stock Issued (Repurchased)	647.53	865.6	354.31
Other Financing Activities	-8.99	-17.64	-7.5
Financing Cash Flow	763.25	847.96	346.81
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.23	-2.99	1.42
Net Cash Flow	198.63	298.79	-328.2
Free Cash Flow	-579.63	-549.17	-675
FCF Margin	-305.94%	-247.08%	-394.01%
Free Cash Flow Per Share	-5.94	-6.76	-10.74
Levered Free Cash Flow	-682.54	-535.41	-840.41
Unlevered Free Cash Flow	-652.73	-524.23	-673.45